Steep cuts at the Food and Drug Administration might slow down drug approvals vital to the biopharma industry.

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

Fact checked by Nick Blackmer Compounded versions of semaglutide, the active ingredient in weight loss drugs like Ozempic and ...

The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, paving the way for a new type of ...

Deputy directors at the FDA center that oversees the regulation of cancer drugs plan to leave, adding to a flood of top ...

FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS ...

FDA sets PDUFA goal date of May 24, 2025MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for ...

The FDA bends its new return to office policy, acknowledging that pantries and conference rooms may not be acceptable ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...